Including Hyperbaric Oxygen Therapy in Medical Treatment Protocol in Sudden Hearing Loss is not Useful

Saygi Gokce, Ibrahim Uysal, K Ozcan, Adin Murat Ozcan, Onur Selcuk, Serdar Uysal, Huseyin Ensari, Dere
2013 Int. Adv. Otol   unpublished
Purpose: The purpose of this study is to research the effect of including the hyperbaric oxygen therapy in medical treatment protocol in sudden hearing loss (SHL). Materials and Methods: Seventy-three patients suffering from SHL with a loss of 30 dB and over in three successive frequencies, who were treated in our clinic were put into two groups, were included in the retrospective study. Thirty-four patients in the first group were given papaverine and corticosteroid treatment. Antiviral
more » ... t. Antiviral therapy was added to 12 patients within this group, due to a history of the existence of upper respiratory infection (URI), which had been present over the previous 14 days. Thirty-nine patients in the second group were given papaverine and corticosteroid treatment, and antiviral therapy was added to 18 patients with a history of URI that had been present over the previous 14 days. Between the 6th and 16th days, patients received hyperbaric oxygen therapy (HBOT). An audiological examination of patients was carried out prior to treatment, and at five days, seven days, one month, and three months after the treatment. Patients in both groups were compared in terms of hearing gain. Results: In a comparison of the two groups, it was determined that both groups were correlated with each other in terms of age (p=0.55), gender (p=0.39), seasonal distribution (p=0.39), duration of hearing loss (p=0.51), presence of tinnitus (p=0.48), and vestibular symptom existence (p=0.82), and there was no difference between groups. A statistically significant change was determined in hearing following treatment in the first group, in comparison to the pre-treatment period (p=0.01). A statistically significant change was also determined in hearing following treatment in the second group, in comparison to the pre-treatment period (p=0.01).Following the comparison of hearing gain of both groups, a no statistically significant difference could found (p=0.89) Discussion: It is believed that many factors exist in the etiology of SHL. Among those, vascular, immunologic, and viral factors were discussed in particular in many studies, and the role of these factors in etiology was not elucidated, although they were frequently regarded as responsible for the development of SHL. Therefore, combining the agents directed to vascular, immunologic, and viral etiology in SHL treatment became an acceptable approach. The combined treatment modality based on the principle of simultaneous usage of more than one agent in SHL treatment was also supported with the results of our study, and is thought to be a highly effective practice. Conclusion: It is believed that the treatment protocol including papaverine, corticosteroid, antiviral agents, and HBOT have a significant effect on the results of SHL treatment. Although including HBOT in medical treatment was observed to provide a hearing gain within the group, following the comparison of both groups, it was determined that it did not cause a statistically significant difference on the results, and more comprehensive and prospective studies are required regarding this subject.
fatcat:xipg5zvpozberdmlmxhbfs37am